BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $512,703 | -16.6% | 7,532 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $614,837 | -2.3% | 7,532 | -11.2% | 0.00% | 0.0% |
| Q1 2023 | $629,057 | -90.0% | 8,479 | -88.9% | 0.00% | -90.0% |
| Q4 2022 | $6,307,168 | +16.7% | 76,100 | +300.0% | 0.01% | +11.1% |
| Q3 2022 | $5,403,000 | -18.1% | 19,025 | +0.5% | 0.01% | -10.0% |
| Q2 2022 | $6,597,000 | -24.5% | 18,929 | -4.1% | 0.01% | -16.7% |
| Q1 2022 | $8,733,000 | +54.3% | 19,742 | +80.4% | 0.01% | +71.4% |
| Q4 2021 | $5,661,000 | -45.5% | 10,941 | -49.0% | 0.01% | -56.2% |
| Q3 2021 | $10,386,000 | -48.1% | 21,434 | -51.8% | 0.02% | -36.0% |
| Q2 2021 | $20,020,000 | +52.3% | 44,465 | +29.2% | 0.02% | +47.1% |
| Q1 2021 | $13,143,000 | -72.9% | 34,413 | -77.5% | 0.02% | -50.0% |
| Q4 2020 | $48,508,000 | +93.3% | 152,754 | +50.3% | 0.03% | -15.0% |
| Q3 2020 | $25,099,000 | -11.4% | 101,657 | -5.2% | 0.04% | -21.6% |
| Q2 2020 | $28,316,000 | +31.0% | 107,232 | -3.5% | 0.05% | +10.9% |
| Q1 2020 | $21,608,000 | -33.4% | 111,068 | -24.9% | 0.05% | -13.2% |
| Q4 2019 | $32,459,000 | -18.5% | 147,870 | -26.7% | 0.05% | -24.3% |
| Q3 2019 | $39,818,000 | +22.1% | 201,785 | +29.0% | 0.07% | +18.6% |
| Q2 2019 | $32,602,000 | -20.5% | 156,373 | -24.3% | 0.06% | -19.2% |
| Q1 2019 | $41,025,000 | +46.7% | 206,625 | +6.9% | 0.07% | +43.1% |
| Q4 2018 | $27,969,000 | -4.6% | 193,269 | +34.6% | 0.05% | +2.0% |
| Q3 2018 | $29,317,000 | -0.7% | 143,632 | -28.4% | 0.05% | -3.8% |
| Q2 2018 | $29,524,000 | -5.0% | 200,664 | -2.4% | 0.05% | -3.7% |
| Q1 2018 | $31,068,000 | -11.7% | 205,698 | -24.3% | 0.05% | -6.9% |
| Q4 2017 | $35,204,000 | -13.4% | 271,740 | -19.3% | 0.06% | -18.3% |
| Q3 2017 | $40,632,000 | +1.0% | 336,811 | -1.8% | 0.07% | -2.7% |
| Q2 2017 | $40,220,000 | +87.0% | 342,815 | +61.0% | 0.07% | +284.2% |
| Q1 2017 | $21,512,000 | +96.8% | 212,906 | +100.3% | 0.02% | -9.5% |
| Q4 2016 | $10,930,000 | -31.9% | 106,300 | -27.5% | 0.02% | -30.0% |
| Q3 2016 | $16,056,000 | -13.3% | 146,633 | -10.7% | 0.03% | -18.9% |
| Q2 2016 | $18,520,000 | +26.4% | 164,233 | +7.1% | 0.04% | +23.3% |
| Q1 2016 | $14,653,000 | -25.6% | 153,333 | -29.9% | 0.03% | -26.8% |
| Q4 2015 | $19,695,000 | -1.4% | 218,833 | +1.3% | 0.04% | -2.4% |
| Q3 2015 | $19,965,000 | +0.7% | 215,933 | +6.9% | 0.04% | +7.7% |
| Q2 2015 | $19,824,000 | +10.0% | 202,033 | +11.0% | 0.04% | +11.4% |
| Q1 2015 | $18,019,000 | -4.5% | 181,933 | -10.9% | 0.04% | -5.4% |
| Q4 2014 | $18,875,000 | – | 204,269 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |